SCHEMBL29664294

SCHEMBL29664294

Cc1ccc(Br)c(CNC(=O)OC(C)(C)C)n1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 1/20 0.44
MAPKAPK2 P49137 3/20 0.44
BCHE P06276 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CA1 P00915 6/20 0.40
CA2 P00918 6/20 0.40
CA12 O43570 5/20 0.40
CA9 Q16790 5/20 0.40
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
NPC1 O15118 1/20 0.39
RECQL P46063 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NAMPT P43490 1/20 0.39
HTT P42858 1/20 0.39
NQO2 P16083 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26093437 0.84 KDM4A (0.41) KDM4AMAPKAPK2BCHEL3MBTL1CA1
SCHEMBL20447809 0.82 KDM4A (0.43) KDM4AMAPKAPK2BCHEL3MBTL1KDM4E
SCHEMBL29578574 0.82 KDM4A (0.43) KDM4AMAPKAPK2BCHEL3MBTL1KDM4E
SCHEMBL31437524 0.82 MAPKAPK2 (0.43) KDM4AMAPKAPK2BCHEL3MBTL1CA1
SCHEMBL31104352 0.79 CA1 (0.44) KDM4ABCHEL3MBTL1CA1CA2
SCHEMBL17680468 0.79 CA1 (0.44) KDM4ABCHEL3MBTL1CA1CA2
SCHEMBL8218002 0.77 CA12 (0.45) KDM4AMAPKAPK2BCHEL3MBTL1CA1
SCHEMBL112919 0.75 NPSR1 (0.49) KDM4ABCHEL3MBTL1CA1CA2
SCHEMBL31505359 0.75 NQO2 (0.47) BCHECA1CA2CA12CA9
SCHEMBL31705342 0.74 KDM4A (0.44) KDM4AL3MBTL1CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034162-A1 IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-01-30 US disclosed
US-12145944-B2 Imidazopyrimidines as EED inhibitors and the use thereof REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-11-19 US disclosed
US-20220227778-A1 IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2022-07-21 US disclosed
EP-3999510-A1 IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF The Regents Of The University Of Michigan (US) 2022-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12145944-B2 Imidazopyrimidines as EED inhibitors and the use thereof EED, EEF1D, EEF1A1 KDM4A 480/4885MAPKAPK2 3509/4885BCHE 3967/4885
US-20250034162-A1 IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF EED, EEF1D, EEF1A1 KDM4A 480/4885MAPKAPK2 3509/4885BCHE 3967/4885
US-20220227778-A1 IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF EED, EEF1D, EEF1A1 KDM4A 480/4885MAPKAPK2 3509/4885BCHE 3967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.